Nicholas Maestas
Vermögen: 903 $ am 31.05.2026
Vermögen: 903 $ am 31.05.2026
Nicholas Maestas worked at Immune Design Corp.
from 2014 to 2019, serving as Senior Director-Corporate Development & Operations in 2019.
From 2019 to 2021, worked at Alector, Inc. as Head-Financial Planning & Analysis.
From 2025 to 2026, worked at Tempest Therapeutics, Inc. as Chief Financial Officer, Secretary & Head-Strategy.
Education includes undergraduate studies at the University of California, Berkeley and an MBA from The Wharton School of the University of Pennsylvania.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 590 ( 0% ) | 903 $ | 31.05.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Finanzdirektor/CFO | 05.06.2026 |
| ALECTOR, INC. | Corporate Officer/Principal | 01.07.2021 |
| IMMUNE DESIGN CORP | Corporate Officer/Principal | 01.07.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Alector, Inc.
Alector, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for Alzheimer’s disease and other neurodegenerative disorders | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology pharmaceuticals | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen